Market Overview:
The global pharmacogenomics technology and theranostics market is expected to grow at a CAGR of 16.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to factors such as rising prevalence of chronic diseases, increasing demand for personalized medicine, and technological advancements in pharmacogenomics technology and theranostics. The sequencing segment is expected to grow at a highest CAGR during the forecast period from 2018 to 2030 owing to technological advancements in this field that have led to increased accuracy and efficiency of sequencing techniques. Based on application, the global pharmacogenomics technology and theragnostics market is divided into oncology, neurological disorders, cardiovascular disease (CVD), immunological disorders, and others. Oncology dominates this market owing high prevalence of cancer across different geographies coupled with increasing demand for targeted therapies for cancer treatment.
 Industry Outlook.svg)
Product Definition:
Pharmacogenomics is the study of how a person’s genes affect their response to drugs. This includes the use of pharmacogenomics technology, which is used to identify and characterize the genetic variants that influence drug response. Pharmacogenomics can be used to develop tailor-made treatments for patients, called personalized medicine or precision medicine. Theranostics is a term that refers to therapies that combine pharmacology (the use of drugs) with diagnostics (the use of tests to detect disease). Companion diagnostics (CDx) are laboratory tests that are used together with a particular therapeutic drug in order to optimize treatment outcomes for patients. CDx tests help doctors determine whether a patient is likely to benefit from a particular therapy, and can also help identify patients who are at risk for adverse effects from certain medications.
PCR:
Polymerase Chain Reaction (PCR) is a technique used in molecular biology for the amplification of DNA. It is an essential tool in pharmacogenomics and helps identify genetic abnormalities, such as oncogenes and tumor suppressor genes. PCR uses a thermostable polymerase to exponentially increase the amount of DNA copy from a specific region known as the probe during each cycle of reaction.
In-situ Hybridization:
In-situ hybridization (ISH) is a technique used for the study of gene expression in situ, that is, inside the cell. The method enables researchers to detect and measure changes in gene expression that occur as a result of physiological or biochemical processes. In-situ hybridization can be used with other molecular techniques such as microarrays and PCR for multiplexed detection of several target genes.
Application Insights:
On the basis of application, the global market is segmented into oncology, neurology, cardiovascular disease and immunological disorders. Oncology accounted for a major share in 2015 owing to increasing prevalence of cancer worldwide. Companion diagnostics plays an important role in providing accurate and fast diagnosis for oncology patients.
The growing importance of pharmacogenomics in cancer management is driven by its ability to identify genetic vulnerabilities that may predict response or resistance to chemotherapeutic drugs. This has led to an increased focus towards companion diagnostics as it can provide faster and more accurate diagnosis than traditional methods such as drug sensitivity testing or tumor progression analysis.
Pharmacogenomics also helps determine optimal dosage schedules, identify new drug targets/interaction mechanisms and develop better treatment options through biomarker-based therapy selection & development phases using bioinformatics tools & data mining techniques with the help from companion diagnostic tests & panels developed from genomic information alone.
Regional Analysis:
North America accounted for the largest share in 2016 owing to the presence of key players, such as Illumina and Roche. The region is expected to maintain its dominance during the forecast period due to continuous developments undertaken by companies operating in this space. For instance, In-situ hybridization technology was commercialized through a sublicense from Agilent Technologies Inc., which allowed easy adoption by clinical laboratories across North America.
Asia Pacific is anticipated to grow at a lucrative rate over the forecast period owing to increasing R&D investments and rising incidences of cancer and other chronic diseases that require companion diagnostics & personalized medicine solutions for effective treatment planning. Japan has been one of the most affected countries globally with respect high incidence rates of cancer along with other chronic diseases; thus, boosting demand for novel therapeutics and diagnostic approaches.-related research activities.-related initiatives are being taken up across Asia Pacific countries including China, India, Singapore among others.
Growth Factors:
- Increasing demand for personalized medicines and therapies
- Growing prevalence of chronic diseases
- Advances in genomic sequencing technologies and bioinformatics
- Proliferation of pharmacogenomics testing services
- Rising number of public-private partnerships and collaborations
Scope Of The Report
Report Attributes
Report Details
Report Title
Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Research Report
By Type
PCR, In-situ Hybridization, Immunohistochemistry, Sequencing, Others
By Application
Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders, Others
By Companies
Qiagen NV, GE Healthcare, Agilent Technologies, F Hoffman La Roche, Foundation Medicine, Thermo Fisher Scientific Inc., Leica Biosystems Nussloch GmBH, Pfizer
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
190
Number of Tables & Figures
133
Customization Available
Yes, the report can be customized as per your need.
Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Report Segments:
The global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) market is segmented on the basis of:
Types
PCR, In-situ Hybridization, Immunohistochemistry, Sequencing, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Qiagen NV
- GE Healthcare
- Agilent Technologies
- F Hoffman La Roche
- Foundation Medicine
- Thermo Fisher Scientific Inc.
- Leica Biosystems Nussloch GmBH
- Pfizer
 Market Overview.svg)
Highlights of The Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- PCR
- In-situ Hybridization
- Immunohistochemistry
- Sequencing
- Others
- By Application:
- Oncology
- Neurological Disorders
- Cardiovascular Disease
- Immunological Disorders
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Pharmacogenomics technology is a field of pharmacology that uses genomic and proteomic methods to identify the effects of drugs on individual patients. Theranostics is a branch of pharmacology that focuses on developing treatments for diseases by using molecularly targeted therapies. Companion diagnostics refers to the use of diagnostic tools in combination with traditional medical care, such as blood tests, imaging scans, and physical exams.
Some of the major companies in the pharmacogenomics technology & theranostics & companion diagnostics (cdx) market are Qiagen NV, GE Healthcare, Agilent Technologies, F Hoffman La Roche, Foundation Medicine, Thermo Fisher Scientific Inc., Leica Biosystems Nussloch GmBH, Pfizer.
The pharmacogenomics technology & theranostics & companion diagnostics (cdx) market is expected to grow at a compound annual growth rate of 16.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size & Forecast, 2018-2028
4.5.1 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Y-o-Y Growth
4.5.2 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Absolute $ Opportunity
Chapter 5 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size Forecast by Type
5.2.1 PCR
5.2.2 In-situ Hybridization
5.2.3 Immunohistochemistry
5.2.4 Sequencing
5.2.5 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size Forecast by Applications
6.2.1 Oncology
6.2.2 Neurological Disorders
6.2.3 Cardiovascular Disease
6.2.4 Immunological Disorders
6.2.5 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Analysis and Forecast
9.1 Introduction
9.2 North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size Forecast by Type
9.6.1 PCR
9.6.2 In-situ Hybridization
9.6.3 Immunohistochemistry
9.6.4 Sequencing
9.6.5 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size Forecast by Applications
9.10.1 Oncology
9.10.2 Neurological Disorders
9.10.3 Cardiovascular Disease
9.10.4 Immunological Disorders
9.10.5 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Analysis and Forecast
10.1 Introduction
10.2 Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size Forecast by Type
10.6.1 PCR
10.6.2 In-situ Hybridization
10.6.3 Immunohistochemistry
10.6.4 Sequencing
10.6.5 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size Forecast by Applications
10.10.1 Oncology
10.10.2 Neurological Disorders
10.10.3 Cardiovascular Disease
10.10.4 Immunological Disorders
10.10.5 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size Forecast by Type
11.6.1 PCR
11.6.2 In-situ Hybridization
11.6.3 Immunohistochemistry
11.6.4 Sequencing
11.6.5 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size Forecast by Applications
11.10.1 Oncology
11.10.2 Neurological Disorders
11.10.3 Cardiovascular Disease
11.10.4 Immunological Disorders
11.10.5 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Analysis and Forecast
12.1 Introduction
12.2 Latin America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size Forecast by Type
12.6.1 PCR
12.6.2 In-situ Hybridization
12.6.3 Immunohistochemistry
12.6.4 Sequencing
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size Forecast by Applications
12.10.1 Oncology
12.10.2 Neurological Disorders
12.10.3 Cardiovascular Disease
12.10.4 Immunological Disorders
12.10.5 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size Forecast by Type
13.6.1 PCR
13.6.2 In-situ Hybridization
13.6.3 Immunohistochemistry
13.6.4 Sequencing
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size Forecast by Applications
13.10.1 Oncology
13.10.2 Neurological Disorders
13.10.3 Cardiovascular Disease
13.10.4 Immunological Disorders
13.10.5 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market: Competitive Dashboard
14.2 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Qiagen NV
14.3.2 GE Healthcare
14.3.3 Agilent Technologies
14.3.4 F Hoffman La Roche
14.3.5 Foundation Medicine
14.3.6 Thermo Fisher Scientific Inc.
14.3.7 Leica Biosystems Nussloch GmBH
14.3.8 Pfizer
